Swiss firm seeks partners for rapid diagnostic nanotechnology platform
This article was originally published in Clinica
Swiss start-up firm Spinomix is seeking partners to collaborate on its rapid diagnostic test platform, which could perform MRSA and SARS tests in under an hour - tests which currently take days to complete.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.